CMT4E

EGR2 | 1998

Illustration of a DNA double helix overlaid on nerve cells, with text reading ‘Experts in CMT: CMT Genes and Subtypes Database

CMT4E is caused by mutations in the EGR2 gene. This gene plays a key role in regulating the development and maintenance of peripheral nerve myelin. Mutations in the EGR2 gene disrupt normal myelin formation, leading to slowed nerve signal transmission.

CMT4E is autosomal recessive, meaning that both of the gene’s copies must have a CMT-causing mutation to cause this subtype.

Clinical Features

Symptom onset in CMT4E typically occurs in infancy or early childhood. Individuals often experience delayed motor milestones and early weakness. Hypotonia in infancy is common, and respiratory insufficiency can occur. Nerve conduction studies usually show severely slowed conduction velocities and somewhat reduced amplitudes, consistent with a demyelinating form of CMT. 

CMT4E symptoms may include:

  • Weakness in the feet and lower legs
  • Muscle atrophy
  • Foot drop
  • A steppage-style walking pattern
  • Reduced sensation
  • Reduced or absent reflexes
  • Foot deformities, including high arches and hammertoes (clawed toes)
  • Progressive involvement of the hands and forearms
  • Difficulty with fine motor skills and manual dexterity
  • Hypotonia
  • Respiratory insufficiency (in infancy in some individuals)
  • Additional symptoms not listed here

Disease Course

CMT4E shows wide variability in severity and progression. Some individuals remain mildly affected, while others develop more severe weakness and functional impairment. Even within the same family, disease severity and progression can differ substantially. Progression is generally slow. Life expectancy can be affected if respiratory insufficiency is not identified and treated early.

Clinical Basics

Subtype
CMT4E

Classification
CMT4

Subtype Alias
Congenital Hypomyelinating Neuropathy 1 (CHN-1)

Neuropathy Type
Demyelinating

Inheritance Pattern
Autosomal Recessive

Genetic Context

HGNC-Approved Gene Symbol
EGR2

Chromosome
10q21.3

Zygosity of Responsible Variant
Homozygous

Mitochondrial Involvement
No

More Info

Research Opportunity

CMT Natural History Study

Original Discovery Publication

Publication Title

Mutations in the Early Growth Response 2 (EGR2) Gene are Associated with Hereditary Myelinopathies

Authors

Warner, L. E., Mancias, P., Butler, I. J., McDonald, C. M., Keppen, L., Koob, K. G., & Lupski, J. R.

Publication Date
April 1, 1998

Updated: February 22, 2026 | By: K. Raymond

The Dorsal Root

More From The Dorsal Root


Close-up of a doctor’s hand holding a prescription pad while a patient’s wrist is wrapped with metal chains.


When Medicine Lost Its Compass

Evidence failed not because it was wrong, but because it was weaponized. I lived the downstream effects of that failure for more than a decade. This is what happens when medicine forgets that data always ends in a human being.


Illustrated graphic showing large ‘404’ numerals with people interacting with data screens and servers, alongside text reading ‘CMT Genetic Testing Error 404: Gene Not Found’ and ‘Examining Why Less Than Half of All Who Have Charcot-Marie-Tooth Disease Are Not Able to Obtain Genetic Confirmation of Their Disease.


Error 404: Gene Not Found

CMT genetic testing often fails to identify the cause of the disease, even when comprehensive panels are used. Here, we discuss why this happens, what genetic tests can and cannot do, and why a negative result still matters.


Illustrated cover graphic showing a split landform with branching directional arrows, two people with question marks above their heads, and the title ‘SORD Deficiency: Decoding This Newly Discovered and Confusing CMT Subtype.


CMT-SORD: What Is This Unique CMT Subtype?

CMT-SORD is a newly discovered CMT subtype driven by toxic sorbitol accumulation. This article explains how "SORD" works, why this subtype is different, and how it led to the fastest-moving therapeutic program in CMT history.